Oruka Therapeutics, Inc.
NASDAQ:ORKABiotechnology
+$0.46 today
- Market cap
- $6.49B
- Beta
- -0.30
- P/E (TTM)
- -33.9
- EPS (TTM)
- -$2.11
Volume 0.52M
Average 1.55M
ORKA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Oruka Therapeutics, Inc.NASDAQ: ORKA
Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026
Selling, general & admin growth accelerates
Q3 FY2026 selling, general & admin of $8.44M rose 64.9% year over year, ahead of the +41.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 24.0% from the prior quarter. Over 3 fiscal years it compounded at +59.4% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +63.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $8.44M+24.0% QoQ
- Last fiscal yearDec 2025
- $21.33M+63.6% YoY
- LTMSep 2026
- $29.26M+41.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +64.9% | -100.0% | -164.9 pp |
| 1 year | +63.6% | -100.0% | -163.6 pp |
| 3-year CAGR | +59.4% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 21.33M USD
- Year-over-year change
- +63.6%
- 4-year CAGR
- +40.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.33M | +63.6% |
| FY2024 | 2024-12-31 | 13.04M | +111.2% |
| FY2023 | 2023-12-31 | 6.17M | +17.3% |
| FY2022 | 2022-12-31 | 5.26M | -2.8% |
| FY2021 | 2021-12-31 | 5.41M | — |
Selling, General & Admin vs competitors
How ORKA compares with its peers on the latest reported figures
- ORKA's LTM Sep 2026 selling, general & admin of $29.26M is the 7th highest of the 10 companies compared; the peer median is $44.15M.
- Its year-over-year change of +41.9% is the 4th highest of 10, against a peer median of +17.2%.
- Over three fiscal years its annual growth of +59.4% compares with a peer median of +16.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $77.08M | +17.2% | +94.2% | 1041.9% |
| LTM Jun 2026 | $65.29M | +5.1% | +10.3% | 62.2% | |
| LTM Mar 2026 | $62.81M | +42.2% | +11.5% | 27.0% | |
| LTM Mar 2026 | $46.46M | +34.5% | +22.2% | — | |
| LTM Jun 2026 | $44.15M | +49.3% | +72.0% | 2318.8% | |
ZURAZura Bio Limited | LTM Mar 2026 | $35.14M | +1.0% | +112.2% | — |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $29.26M | +41.9% | +59.4% | — |
| LTM Mar 2026 | $22.58M | +5.5% | -4.4% | 269.8% | |
| FY2025 | $20.34M | +5.8% | -0.8% | 31781.3% | |
| FY2025 | $13.55M | +83.7% | — | 1003.9% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ORKA) | $44.15M | +17.2% | +16.8% | 1003.9% | |
Competitors are the stored peer set for ORKA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 91K | 114K | 111K | 27K | 83K |
| Gross Profit | (91K) | (114K) | (111K) | (27K) | (83K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.83M | 4.46M | 1.01M | 75.06M | 100.64M |
| Selling, General & Admin | 5.41M | 5.26M | 6.17M | 13.04M | 21.33M |
| Operating Expenses | 19.24M | 9.73M | 7.19M | 88.1M | 121.97M |
| Depreciation & Amortization | 91K | 114K | 111K | 27K | 83K |
| EBITDA | (19.23M) | (9.81M) | (5.23M) | (82.23M) | (105.35M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (19.34M) | (9.84M) | (7.3M) | (88.12M) | (122.05M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 675K | 1.96M | 5.86M | 16.63M |
| Interest Expense | 0 | 0 | 0 | 1.47M | 0 |
| Other Income / Expenses | 13K | (85K) | 1.96M | 4.4M | 16.62M |
| Income Before Tax | (19.32M) | (9.93M) | (5.34M) | (83.72M) | (105.43M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (19.32M) | (9.93M) | (5.34M) | (83.72M) | (105.43M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (16.68) | (8.27) | (4.44) | (4.99) | (2.31) |
| EPS (Diluted) | (16.68) | (8.27) | (4.44) | (4.99) | (2.31) |
| Weighted Avg Shares | 13.9M | 14.41M | 14.42M | 16.79M | 45.61M |
| Weighted Avg Shares (Diluted) | 13.9M | 14.41M | 14.42M | 16.79M | 45.61M |
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Intrinsic Alpha fair value
Locked
Current Price
$95.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.